Prof. Clare Scott, MBBS, PhD, FRACP
Walter and Eliza Hall Institute, Melbourne
‘Pre-clinical models of rare subsets of ovarian cancer: the advantages of purity’
11am-12pm, Wednesday, 4th July 2018

Prof. Clare Scott is a Consultant Medical Oncologist at the Peter MacCallum Cancer Centre and the Royal Melbourne and Royal Women’s Hospitals and is Head of the Ovarian and Rare Cancers Laboratory at the Walter and Eliza Hall Institute of Medical Research. She has 20 years’ experience in treating breast and ovarian cancer and in clinical cancer genetics in Familial Cancer Clinics. Prof. Scott has been Principal Investigator for more than ten ovarian cancer clinical trials of targeted therapy leading to high impact publications. She has developed new ovarian cancer pre-clinical models and is using genomics to study targeted drug combinations to combat drug resistance. Prof. Scott has established a rare cancer research program to improve access to targeted treatments for patients diagnosed with a rare cancer. She was awarded the Sir Edward Dunlop Cancer Research Fellowship from Cancer Council Victoria (2012) and a Clinical Research Fellowship from the Victorian Cancer Agency (2017). She leads the COSA Rare Cancer group and is a member of the International Rare Cancer Initiative Board and Co-Chair of the Gynaecologic Cancer Intergroup (GCIG) Rare Tumour Committee.